U.S. drug giant Bristol Myers Squibb Co (NYSE:BMY) has partnered with Microsoft Inc (NASDAQ:MSFT), aiming to accelerate early detection of lung cancer.
The goal is to deploy U.S. FDA-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network.
The platform, used by more than 80% of U.S. hospitals, applies AI to automatically analyze X-ray and CT scans, helping radiologists identify hard-to-detect lung nodules, flag patients earlier in the disease cycle and reduce clinical workload.
The collaboration aims to expand access to early detection in medically underserved communities, including rural hospitals and community clinics.
Lung cancer remains the leading cause of cancer deaths in the U.S., with about 125,000 deaths and 227,000 new cases each year. Underserved populations face higher mortality rates and lower screening rates, and more than half of patients with incidental findings are lost to follow-up—an issue the partnership seeks to address through workflow tools that track patients and support ongoing care.
“By combining Microsoft’s highly scalable radiology solutions with BMS’ deep expertise in oncology and drug delivery, we’ve envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies,” said Alexandra Goncalves, VP and Head of Digital Health, Bristol Myers Squibb.
Last week, OpenAI acquired the health care technology startup Torch, days after the company unveiled ChatGPT Health, a platform designed to help patients and doctors navigate complex medical information.
Price Action: BMY stock is down 0.81% at $54.81, and MSFT stock is down 1.24% at $454.07 at the last check on Tuesday.
Image: Shutterstock
Recent Comments